CARITI, CATERINA
CARITI, CATERINA
SCIENZE MEDICHE
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors
2022-01-01 Mastorino, Luca; Susca, Sara; Cariti, Caterina; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone; Quaglino, Pietro
Anogenital warts treatment options: a pratical approach
2018-01-01 Delmonte, Sergio; Benardon, Susanna; Cariti, Caterina; Ribero, Simone; Ramoni, Stefano; Cusini, Marco
Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?
2022-01-01 Mastorino L.; Dapavo P.; Avallone G.; Merli M.; Cariti C.; Rubatto M.; Pala V.; Quaglino P.; Ribero S.
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks
2022-01-01 Mastorino, Luca; Cariti, C; Susca, S; Boskovic, S; Aquino, C; Ortoncelli, M; Stroppiana, E; Verrone, A; Dapavo, P; Quaglino, P; Ribero, Simone
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis
2023-01-01 Mastorino, Luca; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Quaglino, Pietro; Ribero, Simone
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients
2022-01-01 Cariti, C; Dapavo, P; Mastorino, L; Ortoncelli, M; Siliquini, N; Merli, M; Avallone, G; Giordano, S; Fabrizio, R; Susca, S; Verrone, A; Stroppiana, E; Quaglino, P; Ribero, S
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
2023-01-01 Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents
2022-01-01 Roccuzzo, Gabriele; Mastorino, Luca; Susca, Sara; Cariti, Caterina; Passerini, Stefania G; Sciamarrelli, Nadia; Borriello, Silvia; Macagno, Nicole; Sliquini, Niccolò; Avallone, Gianluca; Verrone, Anna; Stroppiana, Elena; Quaglino, Pietro; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
2024-01-01 Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease
2020-01-01 Vernero M.; Ribaldone D.G.; Cariti C.; Ribero S.; Susca S.; Astegiano M.; Dapavo P.
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study
2023-01-01 Mastorino L.; Celoria V.; Macagno N.; Cariti C.; Susca S.; Siliquini N.; Ortoncelli M.; Stroppiana E.; Verrone A.; Burzi L.; Quaglino P.; Ribero S.; Dapavo P.
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients
2023-01-01 Mastorino, L; Susca, S; Cariti, C; Sliquini, N; Verrone, A; Stroppiana, E; Ortoncelli, M; Dapavo, P; Ribero, S; Quaglino, P
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
2021-01-01 Dapavo P.; Siliquini N.; Mastorino L.; Avallone G.; Merli M.; Agostini A.; Cariti C.; Viola R.; Stroppiana E.; Verrone A.; Ortoncelli M.; Quaglino P.; Ribero S.
Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient
2020-01-01 Quaglino P.; Fava P.; Cariti C.; Ortoncelli M.; Aimetti M.; Milan A.; Dapavo P.; Tonella L.; Ribero S.; Fierro M.T.
Infections in Sézary syndrome: A retrospective cohort study of 113 patients
2022-01-01 Cariti C.; Quaglino P.; Lupia T.; Novelli M.; Marra E.; Fava P.; Caliendo V.; Tonella L.; De Rosa F.G.; Fierro M.T.; Ribero S.
Mask-related acne flares during the COVID era
2022-01-01 Cariti, Caterina; Cavallo, Francesco; Panzone, Michele; Susca, Sara; Quaglino, Pietro; Ribero, Simone
Melanoma management during the covid-19 pandemic emergency: A literature review and single-center experience
2021-01-01 Cariti C.; Merli M.; Avallone G.; Rubatto M.; Marra E.; Fava P.; Caliendo V.; Picciotto F.; Gualdi G.; Stanganelli I.; Fierro M.T.; Ribero S.; Quaglino P.
Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis
2022-01-01 Avallone G.; Cariti C.; Dapavo P.; Ortoncelli M.; Conforto L.; Mastorino L.; Roccuzzo G.; Cavallo F.; Rubatto M.; Quaglino P.; Ribero S.
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients
2022-01-01 Mastorino, L; Castelli, F; Stroppiana, E; Verrone, A; Ortoncelli, M; Susca, S; Boskovic, S; Passerini, S G; Macagno, N; Cariti, C; Licciardello, M; Solaroli, C; Pertusi, G; Aragone, M G; Baggini, G; Addese, C; Leporati, C; Peila, R; Giura, M T; Rossotto, G; Pella, P; Mocci, L; Merlo, G; Tiberio, R; Graziola, F; Quaglino, P; Dapavo, P; Ribero, S
Sezary syndrome: A single center retrospective study with proposal for a clinical score system
2018-01-01 Quaglino, Pietro; Canonico, Silvia; Cavaliere, Giovanni; Cariti, Caterina; Zocchi, Lamperto; Novelli, Mauro; Astrua, Chiara; Fava, Paolo; Ribero, Simone; Fierro, Maria Teresa
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| "Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors | 2022 | Mastorino, Luca; Susca, Sara; Cariti, Caterina; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone; Quaglino, Pietro | |
| Anogenital warts treatment options: a pratical approach | 2018 | Delmonte, Sergio; Benardon, Susanna; Cariti, Caterina; Ribero, Simone; Ramoni, Stefano; Cusini, Marco | |
| Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? | 2022 | Mastorino L.; Dapavo P.; Avallone G.; Merli M.; Cariti C.; Rubatto M.; Pala V.; Quaglino P.; Ribero S. | |
| Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks | 2022 | Mastorino, Luca; Cariti, C; Susca, S; Boskovic, S; Aquino, C; Ortoncelli, M; Stroppiana, E; Verrone, A; Dapavo, P; Quaglino, P; Ribero, Simone | |
| Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis | 2023 | Mastorino, Luca; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Quaglino, Pietro; Ribero, Simone | |
| Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients | 2022 | Cariti, C; Dapavo, P; Mastorino, L; Ortoncelli, M; Siliquini, N; Merli, M; Avallone, G; Giordano, S; Fabrizio, R; Susca, S; Verrone, A; Stroppiana, E; Quaglino, P; Ribero, S | |
| Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment | 2023 | Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone | |
| Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents | 2022 | Roccuzzo, Gabriele; Mastorino, Luca; Susca, Sara; Cariti, Caterina; Passerini, Stefania G; Sciamarrelli, Nadia; Borriello, Silvia; Macagno, Nicole; Sliquini, Niccolò; Avallone, Gianluca; Verrone, Anna; Stroppiana, Elena; Quaglino, Pietro; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone | |
| Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment | 2024 | Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone | |
| Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease | 2020 | Vernero M.; Ribaldone D.G.; Cariti C.; Ribero S.; Susca S.; Astegiano M.; Dapavo P. | |
| Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study | 2023 | Mastorino L.; Celoria V.; Macagno N.; Cariti C.; Susca S.; Siliquini N.; Ortoncelli M.; Stroppiana E.; Verrone A.; Burzi L.; Quaglino P.; Ribero S.; Dapavo P. | |
| Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients | 2023 | Mastorino, L; Susca, S; Cariti, C; Sliquini, N; Verrone, A; Stroppiana, E; Ortoncelli, M; Dapavo, P; Ribero, S; Quaglino, P | |
| Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study | 2021 | Dapavo P.; Siliquini N.; Mastorino L.; Avallone G.; Merli M.; Agostini A.; Cariti C.; Viola R.; Stroppiana E.; Verrone A.; Ortoncelli M.; Quaglino P.; Ribero S. | |
| Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient | 2020 | Quaglino P.; Fava P.; Cariti C.; Ortoncelli M.; Aimetti M.; Milan A.; Dapavo P.; Tonella L.; Ribero S.; Fierro M.T. | |
| Infections in Sézary syndrome: A retrospective cohort study of 113 patients | 2022 | Cariti C.; Quaglino P.; Lupia T.; Novelli M.; Marra E.; Fava P.; Caliendo V.; Tonella L.; De Rosa F.G.; Fierro M.T.; Ribero S. | |
| Mask-related acne flares during the COVID era | 2022 | Cariti, Caterina; Cavallo, Francesco; Panzone, Michele; Susca, Sara; Quaglino, Pietro; Ribero, Simone | |
| Melanoma management during the covid-19 pandemic emergency: A literature review and single-center experience | 2021 | Cariti C.; Merli M.; Avallone G.; Rubatto M.; Marra E.; Fava P.; Caliendo V.; Picciotto F.; Gualdi G.; Stanganelli I.; Fierro M.T.; Ribero S.; Quaglino P. | |
| Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis | 2022 | Avallone G.; Cariti C.; Dapavo P.; Ortoncelli M.; Conforto L.; Mastorino L.; Roccuzzo G.; Cavallo F.; Rubatto M.; Quaglino P.; Ribero S. | |
| Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients | 2022 | Mastorino, L; Castelli, F; Stroppiana, E; Verrone, A; Ortoncelli, M; Susca, S; Boskovic, S; Passerini, S G; Macagno, N; Cariti, C; Licciardello, M; Solaroli, C; Pertusi, G; Aragone, M G; Baggini, G; Addese, C; Leporati, C; Peila, R; Giura, M T; Rossotto, G; Pella, P; Mocci, L; Merlo, G; Tiberio, R; Graziola, F; Quaglino, P; Dapavo, P; Ribero, S | |
| Sezary syndrome: A single center retrospective study with proposal for a clinical score system | 2018 | Quaglino, Pietro; Canonico, Silvia; Cavaliere, Giovanni; Cariti, Caterina; Zocchi, Lamperto; Novelli, Mauro; Astrua, Chiara; Fava, Paolo; Ribero, Simone; Fierro, Maria Teresa |